TY - JOUR
T1 - Fluorescence-Coupled Ubiquitination Assay as a High-Throughput Screening Strategy for Novel Cereblon Degraders
AU - Deng, Yanan
AU - Yang, Shiling
AU - Xu, Hesong
AU - Ding, Xiyao
AU - Xu, Ying
AU - Ye, Zhengzheng
AU - Chen, Yan
AU - Zhang, Zemin
AU - Lin, Jin
AU - Xiong, Huan
AU - Zhang, Zizhong
AU - Yang, Kun
AU - Hu, Yiran
AU - Xu, Ke
AU - Luo, Cheng
AU - Chen, Shijie
AU - Lin, Hua
AU - Li, Zhihai
N1 - Publisher Copyright:
© 2025 American Chemical Society.
PY - 2025/5/22
Y1 - 2025/5/22
N2 - Cereblon (CRBN)-based protein degradation, via molecular glue degraders (MGDs) and proteolysis-targeting chimeras (PROTACs), is a promising cancer treatment strategy in targeted protein degradation (TPD). However, novel degraders discovery remains limited due to the lack of robust, high-throughput screening (HTS) methods for processing pools of purified compounds or complex chemical synthesis mixtures. Here, we introduce an innovative HTS strategy that employs a highly sensitive, fluorescence-coupled ubiquitination assay to identify CRBN-based degraders. This approach tracks ubiquitinated target proteins via gel-based analyses, and thereby progressively narrows down the list of potential degrader molecules from large-scale compound libraries or chemical reaction mixtures. Using this strategy, we identified LL-BPTF-8, a promising lead compound of PROTAC degrader with high potency and selectivity that targets the bromodomain PHD finger transcription factor (BPTF). Overall, our method offers a low-cost, rapid, and versatile platform for the HTS of protein degrader candidates, significantly streamlining the discovery of novel degraders.
AB - Cereblon (CRBN)-based protein degradation, via molecular glue degraders (MGDs) and proteolysis-targeting chimeras (PROTACs), is a promising cancer treatment strategy in targeted protein degradation (TPD). However, novel degraders discovery remains limited due to the lack of robust, high-throughput screening (HTS) methods for processing pools of purified compounds or complex chemical synthesis mixtures. Here, we introduce an innovative HTS strategy that employs a highly sensitive, fluorescence-coupled ubiquitination assay to identify CRBN-based degraders. This approach tracks ubiquitinated target proteins via gel-based analyses, and thereby progressively narrows down the list of potential degrader molecules from large-scale compound libraries or chemical reaction mixtures. Using this strategy, we identified LL-BPTF-8, a promising lead compound of PROTAC degrader with high potency and selectivity that targets the bromodomain PHD finger transcription factor (BPTF). Overall, our method offers a low-cost, rapid, and versatile platform for the HTS of protein degrader candidates, significantly streamlining the discovery of novel degraders.
UR - https://www.scopus.com/pages/publications/105004479352
U2 - 10.1021/acs.jmedchem.5c00065
DO - 10.1021/acs.jmedchem.5c00065
M3 - 文章
AN - SCOPUS:105004479352
SN - 0022-2623
VL - 68
SP - 10111
EP - 10127
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 10
ER -